The impact of EGFR mutation and PD-L1 status on the efficacy of postoperative radiotherapy in stage III-pN2 NSCLC. Yao J, Geng Y, Xu J, Zou B, et al. BMC Cancer 2025;25:858.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yao J, Geng Y, Xu J, Zou B, et al. The impact of EGFR mutation and PD-L1 status on the efficacy of postoperative radiotherapy in stage III-pN2 NSCLC. BMC Cancer 2025;25:858.
PMID: 40355865